Lung Cancer

Topline phase 3 SAFFRON data showed osimertinib plus savolitinib significantly improved PFS and OS vs chemotherapy in MET-driven, osimertinib-resistant EGFR-mutated NSCLC.

T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.

The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.

William Phillips, MD, discusses real-world findings on RET inhibitor dose reductions and clinical outcomes in advanced RET fusion–positive NSCLC.

Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.

Daniel Boiarsky, MD, discusses tumor-associated macrophages and CD24 expression in patients with metastatic NSCLC.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses the current state and future direction of antibody-drug conjugate development in lung cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.

A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.

Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in NSCLC, rather than sequencing them.

Drs Park and Liu discuss precision oncology, bispecific antibodies, and next-generation targeted therapies in NSCLC.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.

Lung cancer and neurology experts discuss the ties between cancer-associated LEMS and small cell lung cancer, diagnostic tips, and management strategies.